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Abstract  
Two prominent types of synapses in the brain are excitatory and inhibitory, also known 
as glutamatergic and GABAergic synapses, respectively. A precise balance between these two 
types of synapses is required for the proper functioning of the brain. Disturbances to this balance 
have been shown to lead to the development of a number of neurological disorders such as 
schizophrenia, Tourette’s syndrome, autism, and epilepsy. Due to this fact, the study of the 
differential formation of excitatory and inhibitory synapses is important in order to to gain a 
better understanding of the pathology of these diseases. By deciphering the molecular 
mechanisms of correct synapse formation, we can gain insight that will allow for the 
development of effective treatments. In the hippocampus, a specific type of excitatory synapse is 
formed between the axons of the dentate granule cells (DGCs) and dendrites of the CA3 
pyramidal neurons. Fibroblast growth factor-22 (FGF22) has previously been identified as a 
target-derived presynaptic organizer that promotes the differential formation of these 
glutamatergic synapses. However, FGF22 does not work alone in this process, but rather it 
initiates a cascade of molecules that act as mediators of its synaptogenic effect. At present, little 
is known about the mechanism by which FGF22 promotes presynaptic differentiation, including 
the factors involved. Here, I have shown insulin-like growth factor-2 (IGF2) to be a strong 
potential candidate. Through the use of various biochemical techniques, I have gathered data that 
suggests FGF22 regulates IGF2 expression at a specific stage of synaptic development. Along 
with this, my results indicate that IGF2 is required for FGF22-induced synaptic vesicle 
accumulation at the presynaptic terminals on DGC axons. The results of this study further the 
knowledge on this specific synaptic differentiation process, and have taken one step closer to 
finding effective treatments for diseases in which it is involved. 
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Introduction 
The brain is the most complex organ in the body. As the center of the nervous system, the 
brain is responsible for storing our memories, gifting us with the ability to have complex 
thoughts, processing sensory information from the world around us, coordinating our 
movements, and giving us emotion and personality. This organ is truly exceptional in that it is 
able to do all of these things at the same time, with astonishing speed and accuracy. So, what 
exactly allows the brain to precisely govern all of these processes? Simply put, the brain is 
endowed with such complexity because it is composed of a precise architecture of over 100 
billion neurons, which all interact at particular points of contact called synapses. Accurate brain 
function is controlled by specific patterns of synaptic connectivity formed by various types of 
neurons3. Synapses begin to form after growing axons recognize their appropriate targets, and the 
resulting communication between the two is required for synaptic differentiation. Molecules 
released from each side of the synapse, often termed axon and target-derived factors or pre-and 
postsynaptic organizers, are the means of communication between developing synaptic partners1. 
Moreover, the recruitment of synaptic components occurs explicitly at axon-target contact sites, 
implying that molecules exchanged between contacting neurons function as synaptic organizers3. 
Different types of synapses have different components and structures, and serve different 
functions. These differences suggest that the differential formation of each type of synapse 
involves a distinct signaling pathway and a characteristic set of numerous molecular factors3. 
One major category of synapses is glutamatergic, which stimulate excitatory outputs in their 
target neurons. An exact balance between the excitatory outputs and opposing inhibitory signals 
in the hippocampus is vital for proper brain functioning3. Recent studies have revealed the 
existence of glutamatergic and GABAergic synapse-specific organizers3.  
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The differentiation of glutamatergic synapses is accomplished by the successful passing of 
neurons through critical developmental stages, which involve processes facilitated by synaptic 
organizers3. Fibroblast growth factors (FGFs) have previously been identified as a target-derived 
presynaptic organizers2. These proteins are secreted by certain subpopulations of post-synaptic 
neurons and promote the local differentiation of presynaptic axons into functional nerve 
terminals at sites of synaptic contact2. This involves multiples processes, including the clustering 
of synaptic vesicles, the formation of active zones, cytoskeletal restructuring and the assembly of 
vesicle recycling machinery5.	   
In vivo and in vitro studies have 
indicated that one such FGF, FGF22, is 
involved in the differentiation of 
glutamatergic synapses formed between 
axons of dentate gyrus (DG) and 
dendrites of CA3 pyramidal neurons in the 
hippocampus5 (Fig. 1). Previous In vivo studies 
have indicated that FGF22, expressed and 
postsynaptically secreted by CA3 pyramidal neurons, drives presynaptic differentiation early on 
in development1.	   
In situ hybridization has revealed that fgf22 messenger RNAs (mRNAs) are strongly 
expressed in the CA3 of the mouse hippocampus at 8 days after birth (P8)5, approximately the 
time of the onset of synaptogenesis1. Additionally, FGF22 protein localizes to synapse-rich areas 
of the CA3, the stratum radiatum and stratum lucidum. Both of these findings support the idea 
that FGF22 is involved in synapse formation in the CA35. In order to determine whether FGF22 
Figure 1| Hippocampal section showing the 
circuit between the DG and CA3. The dentate 
granule cell axons (red) form synapses with the 
dendrites of the CA3 pyramidal neurons (blue). 
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is required for presynaptic differentiation, the accumulation of synaptic vesicles in FGF22 knock 
out (KO) mice, in which FGF22 expression is defective, was measured relative to wild-type 
(WT) mice. Clustering of synaptic vesicle protein SV2 in the CA3 was shown to be significantly 
decreased in FGF22KO mice at P14, when synaptogenesis is at its peak5. In other areas of the 
hippocampus, such as the CA1, synaptic vesicle clustering was not effected5. Furthermore, 
measurement of the clustering of the active-zone marker bassoon was not significantly different 
between FGF22KO and WT mice. This finding indicated that FGF22 is not involved in active 
zone formation in the development of these synapses5. These results suggest that FGF22 is 
specifically involved in the synaptic vesicles clustering step of presynaptic differentiation 
exclusively in the CA3. 
Synaptic vesicle clustering in FGF22KO mice was not impaired in all synapses of the CA3, 
indicating that FGF22 acts only on a certain subgroup5. The effect of FGF22, particularly on 
glutamatergic presynaptic differentiation in this region, was investigated. This was done by 
measuring the clustering of vesicular glutamate transporter 1 (VGLUT1), which is a protein 
associated with synaptic vesicle membranes and functions in glutamate transport. Clustering of 
vesicular GABA transporter (VGAT), which is an integral membrane protein of synaptic vesicles 
responsible for GABA uptake and storage at inhibitory nerve terminals, was also measured to 
rule out the possibility that FGF22 acts on inhibitory synapse differentiation. At P14 VGLUT1, 
but not VGAT, staining was significantly decreased in the CA3 of FGF22KO mice5. Western 
blots demonstrated that the total amount of VGLUT1 in the CA3 of FGF22KO mice was not 
decreased from its level in WT mice. This suggested that the deficits in presynaptic 
differentiation in FGF22KO mice are due to defects in synaptic vesicle recruitment and not their 
formation5. Additionally, overexpression of FGF22 in cultured hippocampal neurons was shown 
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to induce a significant increase in the clustering of VGLUT1 puncta at the synaptic terminals, 
along the dendrites of FGF22-expressing neurons. These results demonstrate that FGF22’s effect 
on synaptic vesicle clustering is limited to glutamatergic synapses in the CA35.  
So, if FGF22 is a target-derived presynaptic organizer, the differentiation of glutamatergic 
presynaptic terminals on the dendrites of CA3 pyramidal neurons should be specifically impaired 
in FGF22KO mice. This hypothesis was shown to be correct in an in vitro study that utilized the 
measurement of synaptic vesicle clustering at the presynaptic nerve terminals as an indicator of 
synaptic differentiation. CA3 pyramidal neurons were identified using the Py antibody, which 
probes for their dendrites and cell bodies. An anti-VGLUT1 antibody was used to measure 
synaptic vesicle accumulation in these cells. At 14 days in vitro (DIV14), the clustering of 
VGLUT1 on the dendrites of the CA3 was significantly diminished in FGF22KO cultures 
relative to WT. Furthermore, it was shown that this presynaptic defect in FGF22KO cultures 
could be rescued by exogenous FGF22 expression through bath application. These results 
supported the hypothesis that FGF22 is critical for the proper differentiation of excitatory 
presynaptic terminals formed on the CA35. 
To better understand the mechanism that mediates FGF22’s synaptogenic effects, its synaptic 
localization was determined by transfecting hippocampal cell cultures with a plasmid encoding 
enhanced green fluorescent protein (EGFP)-tagged FGF22. It was found that FGF22 localizes to 
CA3 dendrites, as was shown by staining with anti-microtubule-associated protein 2 (MAP2) 
antibodies. In addition, more than 85% of FGF22-EGFP puncta colocalized with postsynaptic 
density protein 95 (PSD95) but not with Gephyrin5, which are postsynaptic scaffolding proteins 
at glutamatergic and GABAergic synapses, respectively. Thus, FGF22 specifically localizes to 
the postsynaptic side of glutamatergic synapses5.  
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The functional consequences of impaired presynaptic differentiation in FGF22KO 
neurons were investigated in two ways. First, miniature excitatory and inhibitory postsynaptic 
currents were measured in FGF22KO hippocampal cultures. It was found that the frequency, but 
not the amplitude, of only excitatory postsynaptic currents were decreased in FGF22KO cultures 
relative to WT5. Second, since a synaptic imbalance in the hippocampus is hypothesized to 
contribute to the development of various neurological disorders, such as epilepsy, FGF22KO and 
control animals were subjected to the kindling protocol. Animals were injected with a GABA 
receptor antagonist to induce epileptic seizures. None of the FGF22KO mice were kindled within 
the period examined whereas half of the control mice were. It seems likely that FGF22 plays a 
role in the formation or maintaining the excitatory-inhibitory balance in the hippocampus. 
Moreover, FGF22KO mice are resistant to induced seizures, probably due to their impaired 
formation of excitatory synapses and therefore greater relative level of inhibitory synapses whose 
correct formation do not depend on FGF225.  
Taken together, the outcomes of these experiments suggest that FGF22 plays a vital role 
in glutamatergic presynaptic differentiation in the CA3 of the hippocampus. Yet, the details of 
molecular mechanism by which FGF22 exerts its effects are not entirely understood. As a target-
derived factor, FGF22 is secreted from the CA3 pyramidal neurons and diffuses across the 
synaptic cleft to the presynaptic nerve terminals of DG axons where it binds to its receptor and 
subsequently induces some intracellular cascade. This cascade ultimately results in the clustering 
of synaptic vesicles at the presynaptic nerve terminals. The study presented here began with the 
intent of identifying other factors involved in this mechanism. 
In order to identify factors that could be involved in the mechanism by which FGF22 
induces synaptic vesicle clustering during glutamatergic presynaptic differentiation, qRT-PCR 
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was used to screen for genes that are downregulated in the dentate gyrus of FGF22KO mice. One 
factor that was found to have decreased mRNA levels in the DG was Insulin-like growth factor-2 
(IGF2). IGF2 was chosen as a strong candidate for a number of reasons. Most importantly it has 
been found that IGF2KO mice are resistant to induced seizures, similar to FGF22KO mice. 
Furthermore, recent studies have provided proof that IGF2 is involved in various processes of 
neurogenesis and synaptogenesis in the hippocampus. IGF2 is involved in adult hippocampal 
neurogenesis by selectively controlling the proliferation of dentate granule neural stem cells7, it 
facilitates a fear extinction pathway in the hippocampus6, and it enhances memory retention and 
prevents forgetting8. 
 Likewise, hippocampal formation has been shown to have some of the most intense and 
abundant IGF2/MP6 receptor (IGF2R) immunoreactivity in the brain10. IGF2R staining 
demonstrates that it is strongly expressed in nearly all CA3 pyramidal neurons10. The fact that 
the receptor for IGF2 has been shown to be located in this area of the hippocampus strongly 
suggests that IGF2 has some influence on the cells in this area. 
 Although the following experiment were performed mostly by me, I am also including 
experiments performed by Akiko Terauchi, my supervisor, directly before I began work on this 
project. With her help, I have developed the following model (Fig. 2) for the role of IGF2 as a 
molecular mediator of excitatory presynaptic differentiation in the hippocampus, including its 
relation to FGF22: Upon binding of FGF22 at its receptor (FGF22R) on DGCs a signal cascade 
is induced that leads to an upregulation of IGF2. IGF2 expression ultimately results in the 
recruitment of synaptic vesicles to the axon terminals of glutamatergic synapses.	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Materials and Methods 
Knockout mice. FGF22KO mice were generated by replacing exon 1 and a part of exon 2 of the fgf22 
gene with the neomycin-resistant gene by means of homologous recombination. 
 
Primary Neuronal Cultures. Dissociated hippocampal cultures were prepared from the brains of  
P0 mice. Using a dissecting microscope, hippocampi were dissected out in a dish containing a 
solution of neurobasal (NB) media and a penicillin/streptomycin mixture then immediately 
placed into a 15-mL falcon tube containing a neurobasal media. The hippocampi-containing 
tubes were placed into a centrifuge (0.5 rcf, 2 minutes, 4˚C). Next, the NB was removed and 
replaced with a trypsin solution (2.5% Trypsin, 0.1% DNase, 0.5% Glucose in HBSS) for cell 
dissociation. The tubes were then placed into a 37˚C water bath and allowed to incubate for 15 
minutes, after which time they were centrifuged (1.0 rcf, 3 minutes, 4˚C) again. The trypsin 
solution was then removed completely and the hippocampi were washed two times with HBSS 
Figure 2| Model for IGF2-dependent 
synaptic vesicle accumulation. First, FGF22 
(orange) is released from the postsynaptic cell 
(CA3 pyramidal neuron, blue) and binds to its 
receptor (purple) on the presynaptic cell (DGC. 
green). Upon binding to the receptor, a message 
is relayed within the cell that signals the 
upregulation of some molecular factor(s) 
required for synaptic vesicle clustering at the 
axon terminal. I propose that IGF2 is a key 
molecular factor involved in synaptic vesicle 
clustering at DGC axon terminals, and that its 
expression regulated by FGF22. 
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(10 mL). HBSS was then removed from the tubes and NB/B27 solution was added (500 µL; 
0.01% L-Glutamine, 0.02% B27 supplement (Invitrogen), 0.01% Penicillin/Streptomycin in NB 
media). Single-cell suspension was performed by pipetting the hippocampi up and down 5-10 
times using a 1 mL pipette tip until no chunks of tissue remained. Cells were counted and then 
re-suspended in the appropriate amount of NB/B27 solution to reach the desired cell 
concentration (3x104 cells/coverglass or 5x104 cells/coverglass for cultures to be transfected). 
Neurons were plated onto poly-D-lysine coated glass coverslips (diameter 12-14mm) and 
maintained in neurobasal medium with B27 supplement in a 5% CO2 incubator at 37˚C. 
 
Transfection. Transfections were performed on cultured hippocampal neurons using the calcium 
phosphate method. Neurons were isolated from the dentate gyrus and CA3 regions of the 
hippocampus (5 X 104 cells/coverslip) and cultured for 1 to 3 days before each coverglass was 
transferred into a single well of a 24 well plate. Each well was filled with 50 µL of transfection 
media (B27 and L-Glutamine in NB). The culture media from each dish was stored in a tube and 
saved for use in a later step. Cells were then incubated in a 5% CO2 incubator for 30 minutes at 
37˚C. During incubation, cDNA solutions were prepared in 1.5 µL centrifuge tubes at a 
concentration of 1-2 µg per coverglass. Additionally, one 1.5 µL centrifuge tube was filled with 
100 µL of HEPES buffer solution for each cDNA tube. The cDNA solutions were then added 
into the HEPES buffer-containing tubes. 1/8 of the cDNA solution was pipetted gently into the 
HEPES buffer at a time and the tubes were vortexed for about 2 seconds following each addition. 
cDNA solutions were allowed to incubate in the HEPES buffer for 20 minutes prior to 
transfection. 50 µL of transfection solution was added to each coverglass and then the 24-well 
plate was placed back into the 5% CO2 incubator for 1 hours and 5 minutes. After incubation, the 
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transfection solution was removed from each well and 10% CO2 saturated NB/B27, prepared at 
least 3 hours prior to use, was added. This was followed by incubation in a 10% CO2 incubator 
for 15 minutes, and then for 5 minutes in a 5% CO2 incubator. Wells were washed two times 
with NB and finally, 350 µL of the saved NB/B27 culture media was added onto each 




For experiments in which IGF2 was overexpressed, two plasmids were used, the first was a 
plasmid encoding IGF2 protein and the second was a synaptophysin-yfp plasmid that allowed 
synaptophysin protein to be viewed by fluorescence microscopy. A plasmid construct encoding 
short hairpin RNA (shRNA) for IGF2 was used as method of RNA interference (RNAi) in 
experiments in which IGF2 expression was knocked down. By this method, IGF2 mRNA was 
targeted for cleavage by the RISC complex of transfected cells, inhibiting translation of the 
mRNA into IGF2 protein. A control shRNA plasmid was also used for these experiments. 
 
Immunocytochemistry. Cultured neurons were fixed with either 4% paraformaldehyde (PFA) for 
10 min at 37°C, methanol for 5 min at -20°C, or acetone for 2 min at -20°C depending on the 
primary antibodies being used. Neurons were blocked for 30 min in 2% BSA, 2% normal goat 
serum, 0.1% Triton X-100, followed by incubation overnight with primary antibodies at 4°C. For 
goat polyclonal antibodies, neurons were blocked for 30 min in 2% BSA, 0.1% Triton X-100, 
and then incubated with primary antibodies. Secondary antibodies were applied for 1 h at 25°C 
and slides were mounted onto glass slides with p-phenylenediamine (PPD). Slides were kept in a 
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-20 ˚C freezer. For experiments in which anti-CR or anti-CB antibodies were used, prox1 was 
stained using the Zenon labeling method (Zenon labeling kit: molecular probes). 
 Dilutions of antibodies used are as follows: anti-VGLUT1 (1:4,000), anti-VGAT 
(1:1,000), anti-PSD95 (1:700), anti-Gephyrin (1:500), anti-Calbindin (1:250 or 1:300 or 
1:1,000), anti-Calretinin (1:250 or 1:200), anti-Prox1 (1:2,000 or 1:500), anti-GFP (1:100 or 
1:500 or 1:3,000), anti-Neurofiliment (1:1,000 or 1:2,500), anti-MAP2 (1:4,000), anti-IGF2 
(1:50), anti-IGF2R (1:70 or 1:150), and the Py antibody (1:20).  
 
Microfluidic Chamber Culture. Coverslips were initially washed and stored at 4˚C in a bottle 
containing 70% ethanol. Before use, coverslips were additionally washed in 10 cm culture dishes 
3 times using sigma water, thoroughly dried, and coated with PDL diluted in boric buffer (4x 
concentration, 8ml/coverslip) overnight in a culture hood. The next day the PDL solution was 
aspirated and coverslips were washed 3 times with sigma water after which they were soaked in 
sigma water for 1-2 hours in a sterile culture hood. After, the water was aspirated and each 
coverslip was placed into a 6 cm culture dish and allowed to dry overnight in a culture hood. The 
preparation of the microfluidic devices began on days after coverslips began to be coated with 
PDL. Devices were washed by placing them into a 10 cm culture dish with their ‘bridge’ side 
facing up and soaking them in 200-proof ethanol for 5-10 minutes. Excess ethanol was then 
removed and the devices were dried overnight in a culture hood. The next day, devices were 
placed onto PDL coated coverslips in 6 cm dishes with the ‘bridge’ side facing down. A 
reversible bond was made by gently pressing down on each device. Hippocampal neurons 
isolated from the DG/CA3, cultured as previously described, were immediately loaded  (7,000 
cells/µL, 5µL) into the somal side of the devices following their attachment to the coverslips. 
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Culture medium was added to the axonal chambers. Cells were then incubated for 10-15 minutes 
in a 37°C, 5% CO2 incubator to facilitate adhesion. Culture medium was then added to both sides 
of the device (100 µL to the axonal side, 150 µL to the somal side). At DIV3, FGF22 was added 
to the axonal side of the device (2nM, 10 µL). Culture medium (30 µL) was also added to the 
somal side to maintain the volume difference between the two chambers. At DIV9, the devices 
were removed from the coverslips by pouring warm neurobasal (4 ml/dish) into the 6 cm dishes 
and gently detaching them using sterile forceps. Cells were fixed in acetone for 2 minutes at -
20°C and then washed 3 times with PBS for 5 minutes each. Cells were then staining using the 
methods previously described. 
 
Imaging. Twelve-bit images were acquired on an epifluorescence microscope (BX61; Olympus) 
using 10x, 20x, or 40x objective lenses and an F-View II CCD Camera (Soft Imaging System) at 
1,376 pixels X 1,032 pixels resolution, or on a confocal microscope (FV1000; Olympus) using a 
40X objective lens at 1,024 pixels X 1,024 pixels resolution. For each experiment, all images 
were acquired with identical settings for laser power, detector gain and amplifier offset. Confocal 
images were acquired as a z-stack (10-25 optical sections, 0.5µm step size). For quantification, 
neurites or random fields were selected, thresholded (the intensity of the dendritic shaft in 
control cultures was calculated as the background fluorescence), and the average size, density 
(per length), and average intensity of puncta were calculated with Metamorph Software. 
Metamorph software was also used for determining the colocalization indices. Images of single 
fluorescence channels were thresholded and binarized. Puncta in one channel were considered to 
be colocalized if their area was covered by the signal a second channel. 
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Results 
 
IGF2 mRNA expression is impaired in the dentate gyrus of FGF22KO mice 
In accordance with the proposed model, IGF2 expression in the DG should be decreased 
by impaired expression of FGF22 in developing CA3 pyramidal neurons. This was verified by an 
experiment done by Akiko Terauchi using in situ hybridization for the Igf2 gene in the 
hippocampus. Igf2 mRNA levels were measured in FGF22KO mice relative to WT mice at P7 
and P14. At P7, there was no significant difference in the amount of IGF2 mRNA between 
FGF22KO and WT mice. However, expression at P14 it was diminished in the inner molecular 
layer of dentate granule cells (DGCs) in the DG of FGF22KO mice. These results support the 
belief that FGF22 regulates presynaptic IGF2 expression from the DG during a specific period of 
synaptogenesis. 
 
IGF2 protein levels are decreased in the inner molecular layer of the DG in FGF22KO 
mice during a specific stage of synaptogenesis. 
Since IGF2 expression was decreased exclusively in the inner cell layer of the DG of 
FGF22KO mice brain sections, this layer-specific expression was investigated by Akiko 
Terauchi. She immunostained WT and FGF22KO brain slices at P7 and P14 with an anti-IGF2 
antibody in addition to ether an anti-Calretinin (CR), to mark the immature inner cell layer of the 
DG, or anti-Calbindin (CB) antibody, to mark the mature outer cell layer. At P7, IGF2 levels did 
not show any appreciable change between FGF22KO and WT brain sections in both the CR and 
CB-positive cell layers. By contrast, at P14 IGF2 expression was significantly reduced in the 
CR-positive cell layer of the DG in FGF22KO mice. No decrease was seen in the CB-positive 
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cell layer. These observations suggested that IGF2 is only regulated by FGF22 at a later stage of 
synaptogenesis and that its regulation does not continue in mature DGCs. 
 
Overexpression of FGF22 results in increased IGF2 expression in Calretinin positive 
dentate granule cells 
To investigate the relationship between FGF22 and IGF2 expression in the hippocampus 
from another perspective, I overexpressed FGF22 protein in cultured hippocampal neurons. In 
this case, the model predicts that FGF22 overexpression should cause increased IGF2 expression. 
I bath applied FGF22 to cultured DG/CA3 neurons at DIV1 and compared IGF2 expression to 
the WT control cultures with no added FGF22. Cells were fixed and stained at DIV7. An anti-
Prox1 antibody was used to immunolabel DGCs so IGF2 expression could be specifically 
visualized in these cells. The intensity of IGF2 antibody immunoreactivity in Prox1-positive cell 
bodies was used as a measure of IGF2 protein expressed in these cells (Fig. 3a). It was found that 
IGF2 expression in FGF22-treated cultures was significantly increased compared to the control 
(Fig. 3b). These results verify the prediction that FGF22 treatment will upregulate the expression 
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 Subsequent experiments were carried out in which anti-CR and anti-CB antibodies were 
used to differentiate between immature and mature Prox1-positive cells, respectively. For these 
experiments, Prox1 was stained using the Zenon labeling method. These experiments gave 
insight into the developmental timing of FGF22’s control over IGF2 expression. As expected, 
IGF2 expression was increased by FGF22 treatment only in CR-positive cells while no change 
was seen in CB-positive cells (Fig. 3c, e). To assure that FGF22 treatment was not influencing 
the expression of IGF2 in the CA3 pyramidal neurons, some cell cultures were probed with anti-
Py antibody and IGF2 expression was analyzed. Bath applied FGF22 had no effect on IGF2 
expression in these cells (Fig. 3d, f), demonstrating that IGF2 specifically acts on the DGCs. So, 
FGF22 seems to be exerting its effects on IGF2 expression only in DGCs during early synapse 
formation, but not later in mature cells.  
 
IGF2 localizes to presynaptic terminals in the axons of dentate granules cells  
The model includes that FGF22 localizes to the CA3 pyramidal neuron dendrites, which 
has already been proven, while IGF2 should localize to DGC axons. To examine the localization 
Figure 3| Bath application of FGF22 protein increases IGF2 expression in immature dentate 
granule cells.  Cultured hippocampal neurons treated and not treated with FGF22. a, Prox1 (red) labeled 
neurons displayed increased IGF2 (green) expression following bath application of FGF22. Data for the 
experiments is shown in b. c, FGF22 treatment enhanced IGF2 expression in Calretinin-positive DGCs 
(red), but did not cause increased expression in Calbindin-positive DGCs, d (also red). Quantification of 
these two results is shown in e. f, IGF2 expression showed no change with FGF22 treatment in CA3 
pyramidal neurons immunolabeled with the PY antibody (red). Corresponding data is displayed 
graphically in g. Data shown in b was obtained from 93-116 cells from 3 independent experiments. e, 
Average IGF2 intensities, displayed as % of control, were measured in 3 independent experiments from 
5-9 cells per experiment. Data in g is from 38-45 cells from 4 independent experiments. Significant 
difference from control: **P< 0.01 by t-test.  
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of IGF2, Akiko Terauchi generated an EGFP-tagged IGF2 expression plasmid, which was used 
to tag IGF2 with enhanced green fluorescence protein. Cultures were probed with an anti-Prox1 
primary antibody to mark DGCs. In addition, half of the cultures were stained with an anti-
Neurofiliment (NF) antibody and the other half with an anti-MAP2 antibody to mark axons and 
dendrites, respectively. The results demonstrated that IGF2 localizes to the axons of Prox1-
positive cells where it is expressed with a punctated pattern. This punctated pattern implied that 
IGF2 was being sequestered at discrete locations along the axon, possibly at nerve terminals. By 
contrast, IGF2 was not localized at the dendrites as expected. 
 
Following the results of the previously mentioned experiment, Akiko Terauchi 
investigated whether IGF2 is located at the axon terminals of the DGCs. To do this, she co-
transfected cultured hippocampal neurons with two plasmids, one encoding synaptophysin-
mCherry (syt-mCherry) and the other encoding IGF2-EGFP. She then looked to see if their 
expression was co-localized. Cultures were also stained with Prox1 to ensure that the cells we 
were observing were DGCs. The results are in compliance with the model, as the majority of 
IGF2-EGFP puncta were co-localized with syt-mCherry puncta, suggesting that IGF2 localizes 
to the synaptic terminals of the DGCs.  
 
 
IGF2 overexpression in dentate granule cells increases synaptic vesicle clustering at 
presynaptic terminals 
I proposed that IGF2 has a direct effect on synaptic vesicle accumulation and will 
therefore, if overexpressed, increase the number of synaptic vesicles recruited to the axon 
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terminals of DGCs. Akiko Terauchi and I carried out experiments in order to test this. A non-
tagged IGF2 expression plasmid was created and at DIV3, it was co-transfected into 
hippocampal cultures with a plasmid encoding syt-YFP, as described previously, using the 
calcium-phosphate method to assure that the two plasmids were taken up into cells 
simultaneously. The purpose of the IGF2 expression plasmid was not to label IGF2 protein but 
only to enhance the expression of IGF2 so that we could focus solely on the expression of syt-
YFP. Cultures were fixed and stained with Prox1 at DIV10. As shown in Figure 4b, syt-YFP 
puncta were significantly increased in cells transfected with the IGF2 expression plasmid 
compared to the control group, which did not receive the IGF2 expression plasmid. These results 
confirm the proposal that IGF2 directly regulates synaptic vesicle accumulation at glutamatergic 
presynaptic terminals. We also wanted to see if overexpressing IGF2 had any effect on synaptic 
vesicle clustering in cells outside of the DG. So, we performed the same experiment, this time 
focusing on syt-YFP puncta in Prox1 negative cells. Fig 4d graphically depicts the results seen in 























Impaired synaptic vesicle accumulation at glutamatergic synapses in the dentate gyrus of 
FGF22KO mice is recued by bath applied IGF2 
The following experiments not only investigated the relationship between IGF2 and 
FGF22, but also the order of their roles in the pathway to induce the accumulation of synaptic 
vesicles at the axon terminals of DGCs. I hypothesized that the application of IGF2 protein to 
FGF22KO DG/CA3 hippocampal neurons in vitro should restore synaptic vesicle accumulation 
Figure 4| Dentate granule cells transfected with an IGF2 overexpression plasmid demonstrate 
enhanced presynaptic differentiation. Cultured hippocampal neurons transfected with the IGF2 
expression plasmid along with the synaptophysin-YFP plasmid. a, Synaptophysin-mCherry (in green) 
puncta clustering was increased in prox1 positive cells (in red) transfected with the IGF2 overexpression 
plasmid compared to the control. b, Graphs for the number and size of synaptophysin-YFP puncta. 
Included 36-44 cells from 5-7 experiments. c, In cultured cells that were prox1 negative, overexpression of 
IGF2 did not change clustering of synaptophysin-mCherry. d, Graphs quantifying the number and size of 
synaptophysin-YFP puncta of 11-13 cells from 2-3 experiments. Error bars are s.e.m. Significant 
difference from control at ***P < 0.0001 by t-test. Scale bars, 10 µm. 
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to a level very close or identical to that found in the DG/CA3 neurons of WT mice. A bath 
application method was used to introduce IGF2 into hippocampal cell cultures of FGF22KO and 
WT mice at DIV1. Untreated FGF22KO cultures displayed impaired synaptic vesicle clustering, 
as determined by staining them with an anti-VGLUT1 antibody. I then looked to see if these 
defects in synaptic vesicle accumulation found could be rescued in FGF22KO cultured by IGF2 
treatment. Following fixation at DIV13, I compared the expression of VGLUT1 in FGF22KO 
and WT cultured Py-positive neurons with and without IGF2 added. The CA3 pyramidal neurons 
were isolated by staining with the Py antibody, which is specific to their axons and dendrites. 
The results display that VGLUT1 accumulation in FGF22KO cultures treated with IGF2 was 
virtually the same as it was in WT cultures (Fig. 5b, a). From this I was able to conclude that 
bath applied IGF2 rescues defects in VGLUT1 accumulation at the presynaptic terminals caused 
by knocking down FGF22. Bath application of IGF2 did not effect VGAT (Fig. 5c,d), PSD95 
(Fig. 5e,f), or Gephyrin (Fig. 5g,h) localization and accumulation, as expected. Therefore, IGF2 
does not have an effect on excitatory postsynaptic differentiation or inhibitory pre and 
postsynaptic differentiation, indicating that it is most likely not involved in synaptic 
differentiation in the hippocampus in a broader sense.  
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Figure 5| Impairment of synaptic vesicle accumulation at excitatory presynaptic terminals of 
FGF22KO mice is restored to normal levels by bath applied IGF2. WT and FGF22KO cultured neurons 
treated and not treated with IGF2. a, VGLUT1 clustering on the dendrites of CA3 pyramidal neurons 
(labeled with Py antibody, red) of WT and FGF22KO mice. Significant defects in clustering of VGLUT1 
puncta on the CA3 dendrites resulted from knocking down FGF22. However, bath application of IGF2 was 
able to rescue these defects, as demonstrated the restoration of VGLUT1 accumulation to essentially the 
amount found normally in WT mice. Graphs of the density and size of VGLUT1 puncta are shown in b. c-h, 
FGF22KO mice did not display significant changes in VGAT, PSD95, or Gephyrin clustering as a result of 
knocking down FGF22 or by treatment with IGF2. Error bars are s.e.m. Data was obtained from 3-10 cells 
from 4-6 independent experiments. Significant difference from control: **P<0.01 by ANOVA followed by 
Tukey test.  
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IGF2 is required for FGF22-induced synaptogenesis after initial synapse formation 
 To verify the order of IGF2-mediated effects on synapse formation in relation to FGF22 
that is proposed by the model, I performed essentially the opposite of the previous experiment. 
The dentate gyrus/CA3 pyramidal neuron region of the hippocampus was dissected from WT 
mice at P0. Endogenous IGF2 expression was knocked down in hippocampal cell cultures using 
shRNA-mediated gene silencing. Cultures we transfected at DIV1 or DIV2 with either the 
shIGF2 plasmid or a control plasmid. Afterwards, FGF22 protein was bath applied to half of the 
experimental and control group cultures to determine if it is able to rescue any defects in synapse 
formation caused by knocking down IGF2 expression. I expected that FGF22 application should 
not restore any defects in synaptic vesicle clustering at DG axon terminals that result from the 
knocking down of IGF2 expression. This is because, in my proposed mechanism, FGF22 is 
expressed prior to, and is the cause of IGF2 expression in the DG. Cell cultures were then either 
fixed at DIV6 or DIV12 to see if there were any differences in the results at these two stages of 
synapse development. Fig. 6 demonstrates that knocking down IGF2 significantly reduced 
synaptic vesicles clustering at DIV12, but not at DIV6. In addition, FGF22 did not have the same 
effect on IGF2 expression at DIV6 and DIV12. At DIV12 (Fig. 6b, d) FGF22 was not able to 
induce synaptic vesicle accumulation in cultures with IGF2 expression knocked down, depicted 
by a reduced number of synaptophysin-YFP puncta/mm. However, at DIV6 (Fig. 6a, c) FGF22 
was still able to increase synaptic vesicle accumulation even in cultures with IGF2 knocked 
down. These results were interpreted to mean that the pathway by which FGF22 induces synaptic 
vesicle accumulation only involves IGF2 during a certain time period during synapse formation.  
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 In addition, to demonstrate that the observed results could not be attributed to any 
negative effects of the shIGF2 constructs on overall wellbeing of DGCs, we analyzed cell 
morphology (Fig. 7). After comparing the cells transfected with the control shRNA and the 
IGF2-shRNA, it was determined that the morphology of transfected cells was the same in both 
cases. Therefore, the shIGF2 plasmid did not seem to be decreasing the observed number and 
size of syt-YFP puncta by negatively impacting cell health.  
 
Figure 6| FGF22 acts as a mediator of FGF22-induced excitatory presynaptic differentiation only during 
a later phase of synaptogenesis. Cultured neurons from the DG/CA3 region of the hippocampus transfected 
with plasmids expressing synaptophysin-YFP and either control shRNA of IGF2-shRNA. a, At DIV6, syt-YFP 
(green) clustering in DGCs (labeled with a prox1 antibody, red) was not significantly effected by knocking 
down IGF2. FGF22 treatment increased the density and size of syt-YFP puncta to the same extent in control 
and shIGF2-treated cultures. The data from which this conclusion was drawn is depicted graphically in c.  b, 
At DIV12, prox1 positive cells demonstrated a substantial decrease in size and number of syt-YFP puncta 
when IGF2 expression was knocked down. This impairment was not rescued by FGF22 bath application. 
Quantification of the density and size of syt-YFP puncta are shown in d. Error bars are s.e.m. Data are from 3-
9 cells from 4-8 independent experiments. Significant difference from control: *P<0.05, **P<0.01, 
***P<0.001 by ANOVA followed by Tukey test.  
 
Figure 7| Knocking down 
shIGF2 by shRNA-mediated 
gene silencing had no effect on 
DGC morphology. Neurons 
obtained from the DG/CA3 
region of the hippocampus of P0 
mice were cultured and then 
transfected at DIV3. Cultured 
were fixed and stained at DIV10 
for morphological observation. 
Cells transfected with control 
shRNA (left) and cells 
transfected with IGF2-shRNA 
(right) displayed identical 
morphology. DGCs were labeled 
with a prox1 antibody (green) 
and transfected cells are shown 
in red. 
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FGF22 application to axons of DGCs using microfluidic culture system 
To further demonstrate the validity of the proposed model, which says that FGF22 is 
secreted from the CA3 pyramidal neurons and initiates a signaling cascade in the pre-synaptic 
DGCs by binding to its receptor on their axons that leads to the downstream activation of IGF2 
expression and induction of synaptic vesicle accumulation, I searched for a way to isolate 
neuronal axons. I decided to use a microfluidic culture system, for which I devised a protocol 
that allowed me to apply FGF22 directly and exclusively to the cell axons in DG/CA3 cultures. 
Microfluidic culture devices have two chambers separated by a bridge with very narrow grooves 
that only allow for the extension of axons from cells plated in the ‘somal chamber’ into the 
‘axonal chamber’. Neurons were dissected from P0 mice, treated with FGF22 at DIV2, and fixed 
at DIV9. If mechanism proposed by the model is correct, then FGF22 treatment to the axons 
should increase IGF2 expression in prox1 positive cells. This experiment has not yet been 
completed, but my initial observations (Fig. 8) have shown that it is likely that FGF22 is causing 
increased IGF2 expression in DGCs. The completion of these experiments will provide the 
strongest evidence that FGF22 acts specifically at DGC axons to upregulate IGF2, if that is 
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Figure 8| Bath 
application of FGF22 
to the axonal chamber 
of microfluidic 
cultured neurons may 
be increasing IGF2 
expression in DGCs. 
Two cells, were chosen 
out of the control and 
FGF22-treated groups to 
represent the results that 
have been obtained so 
far, one having about 
the highest observed 
IGF2 intensity and the 
other about the lowest 
intensity for each group. 
Cell cultures were 
stained with the 
following primary 
antibodies: IGF2 
(green), Prox1 (red), 
Calretinin (blue), along 
with corresponding 
fluorescent secondary 
antibodies. a, Prox1 and 
Calretinin positive cells 
that seemed to be 
extending their axons 
through the bridge to the 
axonal chamber (as 
determined by 
Calretinin staining, 
where FGF22 was 
applied. b,  higher 
magnification images of 
the white boxed in areas 
shown in a. As can be 
seen from these images, 
Calretinin positive 
DGCs to which FGF22 
was applied appear to 
have a greater IGF2 
intensity in the cell 
bodies. However, more 
data must be collected 
and analysis needs to be 
done in order to 
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The IGF2 receptor displays a punctated expression pattern in the axons of dentate granule 
cells and localizes to presynaptic terminals 
 Determining which cells express the IGF2 receptor (IGF2R) is also important because it 
will indicate where IGF2, once expressed and secreted from the presynaptic cells, has it its 
effects. To address this question, I dissected neurons from the DG/CA3 of the hippocampus and 
allowed cultures to grow until DIV12 at which time they were fixed and stained. To start, I 
stained for both Neurofiliment (NF), an intermediate filament protein found in cell axons, and 
Map2, a microtubule associated protein that stabilizes dendritic shape during neuron 
development, along with the IGF2 receptor. As can be seen in Fig. 9a, in prox1 positive cells the 
receptor expressed a punctated pattern in axons and a diffused pattern in the dendrites. This 
expression pattern correlates with the expression pattern of IGF2 itself, which is also punctated 
in axons and diffused in dendrites. This could indicate that IGF2 is acting in an autocrine 
manner, in that it is secreted from the DG presynaptic axon terminals and then subsequently 
binds to its receptor, also located along the axons, thereby triggering a pathway that activates 
synaptic vesicle accumulation. 
 In addition, I looked for potential colocalization of the IGF2 receptor with VGLUT1 (Fig. 
9b, top three panels), VGAT (Fig. 9b, bottom three panels), PSD95 (Fig. 9c, top three panels), 
and Gephyrin (Fig. 9c, bottom three panels), using the immunocytochemistry as described in the 
methods section. The results of these experiments demonstrate that it is likely that the IGF2R is 
colocalized with VGLUT1 and definitely not colocalized with VGAT. It was more difficult to 
determine the extent to which IGF2R puncta colocalize with PSD95 and Gephyrin puncta due to 
the quality of the IGF2R antibody and its possible incompatibility with the fixation methods 
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used. It seemed possible that IGF2R puncta could be colocalized with PSD95 puncta to some 
extent, but did not appear to colocalize at all with Gephyrin. 
 
 
Figure 9| The IGF2 receptor localizes to the presynaptic terminals of DGCs and displays a 
punctated expression pattern in the axons. Neurons from the hippocampus of P0 mice were cultured 
and later fixed and stained at DIV12. The localization of the IGF2 receptor (green) was observed in prox1 
positive neurons (blue). The extent to which the IGF2R colocalized with VGLUT, VGAT, PSD95, and 
Gephyrin (all shown in red) was also noted. a, The IGF2R expression pattern was punctated in the DGC 
axons (immunopositive for NF, in red) but diffused in the dendrites (immunopositive for Map2, also in 
red). b, The majority of IGF2R puncta appeared to colocalize with VGLUT1 puncta, but not with VGAT 
puncta. c, Gephyrin (bottom panel) also did not seem to be notably colocalized with IGF2R puncta. 
However, in the case of PSD95, IGF2R puncta did seem to colocalize, although to a lesser extent than 
they did with VGLUT1 puncta.  
 
	   30	  
Discussion 
 By conducting the experiments in this study, I have been able to verify the role of IGF2 
in glutamatergic presynaptic differentiation. More directly, I have shown that IGF2 is 
upregulated by FGF22 during a specific stage of synaptogenesis to act as a mediator in synaptic 
vesicle accumulation at DGC nerve terminals. By knocking down and overexpressing FGF22 it 
has been shown that IGF2 expression correspondingly is decreased and increased, but only at a 
later stage of synaptogenesis. This regulation of IGF2 by FGF22 was not observed early on 
during synaptic differentiation. Consistent with my proposed hypothesis, IGF2 was shown to 
localize to DGCs where it appeared to aggregate at presynaptic terminals along the axons. The 
role of IGF2 specifically in synaptic vesicle accumulation at excitatory presynaptic terminals was 
elucidated by observing its effect on VGLUT1 clustering and later synaptophysin-YFP 
clustering. IGF2 appeared to have no effect on synaptic vesicle accumulation in non-prox1 
positive cells. The order of the roles of FGF22 and IGF2 in this pathway was clarified by 
observing that FGF22 was not able to rescue defects in synaptic differentiation after knocking 
down IGF2, but IGF2 was able to rescue defects in cells lacking FGF22 expression. These 
results imply that FGF22 regulated IGF2 expression, but IGF2 does not regulated FGF22 
expression. Furthermore, the observed colocalization of the IGF2R with VGLUT1 and to a lesser 
extent PSD95 provided information regarding the cells on which IGF2 acts after it is expressed 
and secreted from the DGCs. Colocalization with VGLUT1 suggests that IGF2 acts in an 
autocrine manner, binding to its receptor on the presynaptic cells and thereby exerting its effect 
on DGCs. On the other hand, colocalization of the IGF2R with PSD95 implies paracrine mode of 
action for IGF2, in that it binds it receptor on the postsynaptic cells and initiates some molecular 
cascade in the CA3 pyramidal neurons. Alternatively, IGF2 could be acting on both the pre- and 
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postsynaptic cells. Further work is needed to discern between these possibilities. Ultimately, the 
results of this study are significant because they have shed light on the molecular mechanism 
controlling the differentiation of this type of glutamatergic synapse and how defects in this 
mechanism are able to cause impaired synapse formation. Now that this information is known 
we can investigate the role of this specific mechanism in the development of neurological 
disorders, such as epilepsy, and use it for the development of possible treatments.  
 The results of this study have illuminated the need for further research on this mechanism 
and the specific roles of FGF22 and IGF2. It still must be determined exactly where IGF2 acts 
after being secreted from the DGCs, and whether IGF2’s effect is direct or whether other factors 
are recruited by IGF2 to induce synaptic vesicle accumulation. In addition, the expression of 
FGF22 and IGF2 in epileptic patients and/or in animal models of epilepsy is should be examined 
for any abnormalities. Moreover, treatments involving the application of IGF2 and FGF22 
should be investigated for the ability to reduce the occurrence of seizures or alleviate them 
completely. In addition, corresponding factors involved in inhibitory synapse formation in the 
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